Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 1
1980 1
1982 2
1984 1
1986 3
1987 2
1988 1
1989 5
1990 3
1991 3
1992 3
1993 6
1994 7
1995 9
1996 8
1997 7
1998 12
1999 15
2000 10
2001 14
2002 24
2003 25
2004 26
2005 30
2006 36
2007 33
2008 31
2009 36
2010 43
2011 39
2012 37
2013 52
2014 71
2015 60
2016 80
2017 88
2018 103
2019 87
2020 83
2021 91
2022 85
2023 73
2024 34

Text availability

Article attribute

Article type

Publication date

Search Results

1,208 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Substance Adverse Event"
Page 1
Creatine supplementation improves performance, but is it safe? Double-blind placebo-controlled study.
Almeida D, Colombini A, Machado M. Almeida D, et al. J Sports Med Phys Fitness. 2020 Jul;60(7):1034-1039. doi: 10.23736/S0022-4707.20.10437-7. J Sports Med Phys Fitness. 2020. PMID: 32597619 Clinical Trial.
RESULTS: Creatine monohydrate supplementation did not cause adverse events and, as expected, promoted an increase of the performance and body weight. No modification of red blood cells parameters, white blood cells profile, blood lipid profile, metabolic and urine m …
RESULTS: Creatine monohydrate supplementation did not cause adverse events and, as expected, promoted an increase of the perfo …
Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta-analysis.
Bahji A, Bach P, Danilewitz M, Crockford D, El-Guebaly N, Devoe DJ, Saitz R. Bahji A, et al. Addiction. 2022 Oct;117(10):2591-2601. doi: 10.1111/add.15853. Epub 2022 Mar 15. Addiction. 2022. PMID: 35194860 Free PMC article. Review.
Outcomes included incident seizures, delirium tremens, AW severity scores, adverse events, dropouts, dropouts from adverse events, length of hospital stay, use of additional medications, total benzodiazepine requirements, and death. ...Oxcarbaze …
Outcomes included incident seizures, delirium tremens, AW severity scores, adverse events, dropouts, dropouts from a …
Associations Between Adverse Childhood Experiences, High-Risk Behaviors, and Morbidity in Adulthood.
Campbell JA, Walker RJ, Egede LE. Campbell JA, et al. Am J Prev Med. 2016 Mar;50(3):344-352. doi: 10.1016/j.amepre.2015.07.022. Epub 2015 Oct 21. Am J Prev Med. 2016. PMID: 26474668 Free PMC article.
INTRODUCTION: Adverse childhood experiences (ACEs) are associated with early mortality and morbidity. ...Multiple logistic regression assessed the independent relationship between ACE score categories and risky behaviors/comorbidities in adulthood, and assessed the …
INTRODUCTION: Adverse childhood experiences (ACEs) are associated with early mortality and morbidity. ...Multiple logistic regression …
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group. Grebely J, et al. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6. Lancet Gastroenterol Hepatol. 2018. PMID: 29310928 Free article. Clinical Trial.
Drug use before and during treatment did not affect SVR12. Treatment-related adverse events were seen in 48 (47%) patients (one grade 3, no grade 4). Seven (7%) patients had at least one serious adverse event; only one such event (rhabdomyolysis …
Drug use before and during treatment did not affect SVR12. Treatment-related adverse events were seen in 48 (47%) patients (on …
Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP, Keating GM. Garnock-Jones KP, et al. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Paediatr Drugs. 2009. PMID: 19445548 Review.
The majority of adverse events were mild or moderate; there was a very low incidence of serious adverse events. Few patients discontinued atomoxetine treatment because of adverse events. Atomoxetine discontinuation appeared to be well tol …
The majority of adverse events were mild or moderate; there was a very low incidence of serious adverse events. …
Unpacking the impact of adverse childhood experiences on adult mental health.
Merrick MT, Ports KA, Ford DC, Afifi TO, Gershoff ET, Grogan-Kaylor A. Merrick MT, et al. Child Abuse Negl. 2017 Jul;69:10-19. doi: 10.1016/j.chiabu.2017.03.016. Epub 2017 Apr 15. Child Abuse Negl. 2017. PMID: 28419887 Free PMC article.
Dichotomous variables corresponding to each of the 11 ACE categories were created, with ACE score ranging from 0 to 11 corresponding to the total number of ACEs experienced. ...Results indicated a graded dose-response relationship between the expanded ACE score and …
Dichotomous variables corresponding to each of the 11 ACE categories were created, with ACE score ranging from 0 to 11 corresponding …
Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the adverse childhood experiences study.
Dube SR, Felitti VJ, Dong M, Chapman DP, Giles WH, Anda RF. Dube SR, et al. Pediatrics. 2003 Mar;111(3):564-72. doi: 10.1542/peds.111.3.564. Pediatrics. 2003. PMID: 12612237
METHODS: We examined the relationship between illicit drug use and 10 categories of adverse childhood experiences (ACEs) and total number of ACEs (ACE score). ...The persistent graded relationship between the ACE score and initiation of drug use for 4 success …
METHODS: We examined the relationship between illicit drug use and 10 categories of adverse childhood experiences (ACEs) and total nu …
Beyond benzodiazepines: a meta-analysis and narrative synthesis of the efficacy and safety of alternative options for alcohol withdrawal syndrome management.
Fluyau D, Kailasam VK, Pierre CG. Fluyau D, et al. Eur J Clin Pharmacol. 2023 Sep;79(9):1147-1157. doi: 10.1007/s00228-023-03523-2. Epub 2023 Jun 28. Eur J Clin Pharmacol. 2023. PMID: 37380897 Review.

Meta-analysis favored gabapentin over chlordiazepoxide and lorazepam (d = 0.563, p < 0.001) and carbamazepine over oxazepam and lorazepam (d = 0.376, p = 0.029), for reducing Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) scale scores. Eleven non

…

Meta-analysis favored gabapentin over chlordiazepoxide and lorazepam (d = 0.563, p < 0.001) and carbamazepine over oxazepam and lorazepam

…
Atomoxetine.
Simpson D, Perry CM. Simpson D, et al. Paediatr Drugs. 2003;5(6):407-15; discussion 416-7. doi: 10.2165/00128072-200305060-00005. Paediatr Drugs. 2003. PMID: 12765489 Review.
Atomoxetine was well tolerated in clinical trials and discontinuation rates due to adverse events were low (<5%). The most common treatment-related adverse event was decreased appetite. Atomoxetine shows no abuse potential and is not a controlled …
Atomoxetine was well tolerated in clinical trials and discontinuation rates due to adverse events were low (<5%). The most …
Baclofen for alcohol withdrawal.
Liu J, Wang LN. Liu J, et al. Cochrane Database Syst Rev. 2017 Aug 20;8(8):CD008502. doi: 10.1002/14651858.CD008502.pub5. Cochrane Database Syst Rev. 2017. PMID: 28822350 Free PMC article. Updated. Review.
For the comparison of baclofen and placebo (1 study, 31 participants), there was no significant difference in Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) scores (very low quality evidence). For the comparison of baclofen and diazepam (1 stu …
For the comparison of baclofen and placebo (1 study, 31 participants), there was no significant difference in Clinical Institute Withdrawal …
1,208 results